Movement disorders with phosphodiesterase 10A IgG autoimmunity
Objective: To report four new cases of phosphodiesterase 10A (PDE10A) IgG neurological autoimmunity. Background: PDE10A IgG was recently identified as a biomarker of paraneoplastic neurological…IMPACT OF COVID 19 ON PARKINSON’S DISEASE: A CROSS SECTIONAL STUDY
Objective: To review the impact of Covid 19 on symptoms and signs of Parkinsons as well as general being in patients with Parkinson’s Disease at…Characterising Natural Killer cells in early Parkinson’s disease
Objective: To determine whether the number and phenotype of Natural Killer (NK) cells in the blood is altered in early Parkinson’s disease (PD). Background: Accumulating…Mortality in Parkinson’s patients following Covid19 infection in the second wave of the pandemic
Objective: To analyze causes of mortality and death certification in Parkinson’s disease patients who had SARS- CoV2 in Reading, West Berkshire, United Kingdom (UK) Background:…Can treatment of Helicobacter pylori decrease Parkinson’s disease risk?
Objective: The aim of this study was to investigate the association between Helicobacter pylori (H. pylori) infection and the risk of Parkinson’s disease (PD). Background:…Inflammatory changes in subjects with de novo Parkinson’s disease
Objective: To examine whether inflammation is present in subjects newly diagnosed with Parkinson’s disease (PD). Background: Evidence for the role of inflammation in PD has…Blood microRNA-7 as a Progression Biomarker in Parkinson’s disease
Objective: This study investigates the use of microRNA-7-5p (miR-7-5p) as a potential biomarker for Parkinson’s disease (PD) progression. Background: MiR-7-5 is a microRNA that regulates…Microglial activation facilitates alpha synuclein propagation and neurodegeneration in αSyn preformed fibrils (PFF)-injected PD mouse model
Objective: To evaluate whether microglial activation aggravates synucleinopathy progression in Parkinson's disease (PD) mouse model. Background: Alpha-synuclein (αSyn) accumulation underlay the main pathological process of…Inflammatory biomarkers in newly diagnosed patients with Parkinson’s disease
Objective: To identify a panel of cerebrospinal fluid (CSF) inflammatory biomarkers for Parkinson’s disease (PD) and to compare levels of inflammatory proteins in control subjects…SCFAs participate in the pathogenesis of Parkinson’s disease by regulating NLRP3 inflammasomes activation
Objective: To explore the role and related mechanism of gut microbiota metabolites short-chain fatty acids(SCFAs) in the pathogenesis of Parkinson's disease(PD). Background: Growing research have…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 25
- Next Page »